Epigral Share Price

    NSE
    1805.6
    +5.40 (0.28%)
    EPIGRAL • 30 Jun, 2025 | 03:29 PM
    BUY

    1Y Annualised Return

    23.05%

    3Y Annualised Return

    10.56%

    The current prices are delayed, login or Open Demat Account for live prices.

    Epigral Stock Performance

    1W Return4.03
    1Y Return36.48
    Today's Low1789
    Prev. Close1,800.20
    Mkt Cap (Cr.)7,800.82
    1M Return1.58
    3Y Return41.94
    52-Week High2406.75
    Open1,815.00
    PE Ratio22.16
    6M Return-3.14
    Today's High1834.9
    52-Week Low1341
    Face Value10

    Epigral Company background

    Founded in: 2007
    Managing director: Maulik Jayantibhai Patel
    Epigral Limited was erstwhile incorporated as Meghmani Finechem Limited in 2007, which is engaged in manufacturing and selling of Chlor Alkali its Derivatives and also in Trading of Agrochemical products. The Company was incorporated as a subsidiary of Meghmani Organics Limited. Meghmani Finechem Limited (MFL) was demerged from Meghmani Organics Limited (MOL) as a going concern, through the Scheme of Arrangement for Demerger and the said Scheme became effective from May 10, 2021. The ChlorAlkali business commissioned in 2009, growing from an installed capacity of 1,88,000 TPA in 2015 to 3,15,000 TPA at the close of FY 202021. The Company is now among the leading players in Indias chlor alkali industry. In terms of the said Scheme, the Company allotted 2,39,03,029 Equity Shares of Rs 10/ each on 20th May, 2021 to the shareholders of Meghmani Organics Limited.The Company grew its business following the commissioning of new plants (Caustic Soda, Hydrogen Peroxide and the 36 MW Captive Power Plant). The timely commissioning of the plants represented the faith of the management in the longterm potential of the sector and country. The Caustic Soda capacity was expanded by 1,27,000 TPA to 2,94,000 TPA and commissioned in June 2020. The Captive Power Plant capacity was increased by 36 MW to 96 MW, commissioned in June 2020. The Company commissioned a 60,000 TPA Hydrogen Peroxide plant in July 2020. The Company further commissioned the capacity expansion of Caustic Soda manufacturing facility to 400 KTPA by adding 106 KTPA facility, along with expansion of 36 MW Captive Power Plant on 30th September, 2022. It commissioned Epichlorohydrin (ECH) manufacturing facility with a capacity of 50,000 TPA on 1st June, 2022, which is used in varied applications, such as Epoxy Resin, Water Treatment Chemicals, Textiles, Pharmaceuticals, Paper Reinforcement, Synthetic Glycerine, etc. It commissioned CPVC Resinmanufacturing facility with a capacity of 30,000 TPA capacity on 18th July, 2022.In 202425, Company commissioned additional capacity of 45,000 TPA of CPVC Resin facility in April, 2024, reaching total capacity of CPVC Resin to 75,000 TPA. It also forward integrated and commissioned CPVC Compound facility of 35,000 TPA in June, 2024. Company has announced expansion of additional 75,000 TPA capacity of CPVC Resin plant at its Dahej facility in Gujarat. With this expansion, Companys total CPVC resin capacity reaches a remarkable 1,50,000 TPA in FY25. Company has commissioned Indias First Chlorotoluenes Value Chain Facility at its Dahej Complex in Gujarat on 24th March, 2025.

    As of 30 Jun, 2025, Epigral share price is ₹1808.2. The stock opened at ₹1815 and had closed at ₹1800.2 the previous day. During today’s trading session, Epigral share price moved between ₹1,789.00 and ₹1,834.90, with an average price for the day of ₹1811.95. Over the last 52 weeks, the stock has recorded a low of ₹1,341.00 and a high of ₹2,406.75. In terms of performance, Epigral share price has declined by 4.2% over the past six months and has increased by 23.05% over the last year.

    Read More
    Epigral SIP Return Calculator

    Over the past

    1 year
    3 years

    Total Investment of ₹65,00,000

    Would have become ₹73,13,010 (+12.51%)

    Daily SIP of 25,000 would have become 73,13,010 in 1 year with a gain of 8,13,010 (+12.51%)

    View details of Market Depth

    Epigral Fundamental

    Market Cap (in crs)

    7,800.82

    Face Value

    10

    Turnover (in lacs)

    840.42

    Key Metrics

    Qtr Change %
    34.84% Gain from 52W Low
    -5
    Dividend yield 1yr %
    Below industry Median
    0.6

    Epigral Key Financials

    View more

    *All values are in ₹ Cr.

    *All values are in ₹ Cr.

    *All values are in ₹ Cr.

    *All values are in ₹ Cr.

    Epigral Quarterly Revenue
    Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024
    627.63 Cr
    645.24 Cr
    626.06 Cr
    651.2 Cr
    524.63 Cr
    Epigral Yearly Revenue
    Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021
    2565.34 Cr
    1935.76 Cr
    2196.38 Cr
    1555.05 Cr
    830.79 Cr
    Epigral Quarterly Net Profit/Loss
    Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024
    86.62 Cr
    103.54 Cr
    80.53 Cr
    86.01 Cr
    76.67 Cr
    Epigral Yearly Net Profit/Loss
    Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021
    356.7 Cr
    195.84 Cr
    353.31 Cr
    252.79 Cr
    100.84 Cr

    Epigral Result Highlights

    • Epigral Ltd reported a 18.9% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Mar (Q4FY25). On a year-on-year (YoY) basis, it witnessed a decline of 7.2%.

    • Its expenses for the quarter were down by 16.6% QoQ and 9.5% YoY.

    • The net profit decreased 25.4% QoQ and increased 0.7% YoY.

    • The earnings per share (EPS) of Epigral Ltd stood at 18.6 during Q4FY25.

      Read more

    Data Source: BSE, Company announcements

    The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results.

    Top Mutual Fund Invested in Epigral

    Promoter
    69%
    Foreign Institutions
    3%
    Mutual Funds
    4.5%
    Domestic Institutions
    4.7%
    Public
    23.3%
    Promoter
    68.9%
    Foreign Institutions
    3%
    Mutual Funds
    4.2%
    Domestic Institutions
    4.3%
    Public
    23.7%
    Promoter
    71.6%
    Foreign Institutions
    2.1%
    Mutual Funds
    1%
    Domestic Institutions
    1.2%
    Public
    25.1%
    Promoter
    71.6%
    Foreign Institutions
    1.5%
    Domestic Institutions
    0.2%
    Public
    26.8%
    Promoter
    71.5%
    Foreign Institutions
    1.4%
    Public
    27.1%
    Promoter
    71.4%
    Foreign Institutions
    1.2%
    Public
    27.4%

    Epigral Technical Analysis

    Moving Averages Analysis
    1805.6
    Current Price
    Bullish Moving Averages
    10
    Bearish Moving Averages
    6
    5Day EMA
    1,796.40
    10Day EMA
    1,790.10
    12Day EMA
    1,790.20
    20Day EMA
    1,794.40
    26Day EMA
    1,798.20
    50Day EMA
    1,808.70
    100Day EMA
    1,822.30
    200Day EMA
    1,792.40
    5Day SMA
    1,797.80
    10Day SMA
    1,775.00
    20Day SMA
    1,791.00
    30Day SMA
    1,807.90
    50Day SMA
    1,818.40
    100Day SMA
    1,816.00
    150Day SMA
    1,844.80
    200Day SMA
    1,912.20
    Delivery & Volume

    Delivery & Volume

    PeriodCombined Delivery VolumeNSE+BSE Traded Volume
    Day Rs
    29622 Rs
    49764 Rs
    Week Rs
    22868 Rs
    43281 Rs
    Month Rs
    18611 Rs
    37415 Rs
    1,810.70
    Pivot
    Resistance
    First Resistance
    1,832.40
    Second Resistance
    1,856.60
    Third Resistance
    1,878.30
    Support
    First Support
    1,786.50
    Second support
    1,764.80
    Third Support
    1,740.60
    Relative Strength Index
    51.64
    Money Flow Index
    50.65
    MACD
    -8
    MACD Signal
    -12.41
    Average True Range
    59.78
    Average Directional Index
    17.21
    Rate of Change (21)
    1.58
    Rate of Change (125)
    -4.25
    Name
    Holding Percent
    Hsbc Focused Fund
    2.77

    Epigral Latest News

    30 JUN 2025 | Monday

    Epigral Ltd - 543332 - Shareholder Meeting / Postal Ballot-Scrutinizer''s Report

    28 JUN 2025 | Saturday

    Epigral Ltd - 543332 - Shareholder Meeting / Postal Ballot-Outcome of AGM

    27 JUN 2025 | Friday

    Epigral Ltd - 543332 - Closure of Trading Window

    View More

    Epigral Share Price FAQs

    Epigral share price is ₹1805.6 in NSE and ₹1808.65 in BSE as on 30/6/2025.

    Epigral share price in the past 1-year return was 36.48. The Epigral share hit a 1-year low of Rs. 1341 and a 1-year high of Rs. 2406.75.

    The market cap of Epigral is Rs. 7800.82 Cr. as of 30/6/2025.

    The PE ratios of Epigral is 22.16 as of 30/6/2025.

    The PB ratios of Epigral is 4.09 as of 30/6/2025

    The Mutual Fund Shareholding in Epigral was 4.48% at the end of 30/6/2025.

    You can easily buy Epigral shares in Kotak Securities by opening a demat account and getting the KYC documents verified online.

    The 52-week high and low of Epigral share price is ₹2406.75 and ₹1341 as of 30/6/2025.

    Please be aware that Epigral stock prices are subject to continuous fluctuations due to various factors.

    Popular Stocks
    820.35
    +14.95 (+1.86%)
    1,500.60
    -14.80 (-0.98%)
    2,001.50
    -13.40 (-0.67%)
    1,601.80
    -6.20 (-0.39%)
    3,462.00
    +20.90 (+0.61%)
    Top Gainers
    6,217.50
    +198.00 (+3.29%)
    820.35
    +14.95 (+1.86%)
    421.50
    +7.00 (+1.69%)
    872.10
    +14.40 (+1.68%)
    326.75
    +3.30 (+1.02%)
    Top Losers
    1,098.90
    -25.40 (-2.26%)
    1,199.20
    -25.90 (-2.11%)
    2,163.50
    -44.40 (-2.01%)
    4,237.10
    -83.20 (-1.93%)
    12,400.00
    -242.00 (-1.91%)
    Open Demat Account
    +91 -

    Open Demat Account
    +91 -